Vineet Laboratories Limited (VINEETLAB) - Total Liabilities

Latest as of September 2025: Rs764.24 Million INR ≈ $8.26 Million USD

Based on the latest financial reports, Vineet Laboratories Limited (VINEETLAB) has total liabilities worth Rs764.24 Million INR (≈ $8.26 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore VINEETLAB shareholders equity momentum to track the company's year-over-year net asset growth rate.

Vineet Laboratories Limited - Total Liabilities Trend (2017–2025)

This chart illustrates how Vineet Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Vineet Laboratories Limited to measure how efficiently the company converts operating cash flow to free cash.

Vineet Laboratories Limited Competitors by Total Liabilities

The table below lists competitors of Vineet Laboratories Limited ranked by their total liabilities.

Company Country Total Liabilities
DarkIris Inc. Class A Ordinary Shares
NASDAQ:DKI
USA $1.66 Million
Khaitan (India) Limited
NSE:KHAITANLTD
India Rs444.93 Million
Intanwijaya Internasional Tbk
JK:INCI
Indonesia Rp73.38 Billion
Puri Global Sukses Tbk Pt
JK:PURI
Indonesia Rp428.63 Billion
Touchwood Entertainment Limited
NSE:TOUCHWOOD
India Rs133.18 Million
Mason Graphite Inc.
V:LLG
Canada CA$149.56K
PYRAMID AG NA KONV.
XETRA:M3B0
Germany €32.68 Million
PATRYS Ltd
AU:PAB
Australia AU$1.01 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Vineet Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VINEETLAB stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 5.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.84 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vineet Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vineet Laboratories Limited (2017–2025)

The table below shows the annual total liabilities of Vineet Laboratories Limited from 2017 to 2025.

Year Total Liabilities Change
2025-03-31 Rs798.92 Million
≈ $8.64 Million
-2.75%
2024-03-31 Rs821.48 Million
≈ $8.88 Million
-0.02%
2023-03-31 Rs821.66 Million
≈ $8.89 Million
-18.17%
2022-03-31 Rs1.00 Billion
≈ $10.86 Million
+22.27%
2021-03-31 Rs821.26 Million
≈ $8.88 Million
+20531525.00%
2020-03-31 Rs4.00K
≈ $43.26
-94.65%
2019-03-31 Rs74.78K
≈ $808.72
-35.80%
2018-03-31 Rs116.48K
≈ $1.26K
+1064.80%
2017-03-31 Rs10.00K
≈ $108.15
--

About Vineet Laboratories Limited

NSE:VINEETLAB India Chemicals
Market Cap
$7.97 Million
Rs736.56 Million INR
Market Cap Rank
#27590 Global
#1541 in India
Share Price
Rs38.35
Change (1 day)
-3.23%
52-Week Range
Rs29.01 - Rs47.87
All Time High
Rs117.46
About

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl… Read more